1. The basic situation of the meeting
(1) Number of shareholders meeting
This meeting is the 2020 Annual General Meeting of Shareholders.

(2) Convener
The convener of this general meeting of shareholders is the board of directors.
none

(3) The legality and compliance of the meeting
The convening and time, method, convener and moderator of this general meeting of shareholders are in compliance with the "Company Law of the People's Republic of China", "Articles of Association of Shanghai Yan'an Pharmaceutical Yangpu Co., Ltd." and "Rules of Procedures for the General Meeting of Shareholders" and other relevant laws and regulations Regulation.

(4) Method of convening the meeting
The meeting was held by on-site voting.
none

(5) Date and time of the meeting
1. On-site meeting time: 13:30 on May 13, 2021.
Other voting methods: none

(6) Attendance
1. Shareholders who hold the company's shares on the date of equity registration.
All shareholders of the company registered with ChinaClear at the end of the afternoon on the equity registration day (see the table below for details) are entitled to attend the general meeting (investors who bought securities on the equity registration day have this right, and sold on the equity registration day Securities investors do not have this right), shareholders can appoint an agent in writing to attend the meeting and vote, and the shareholder agent does not have to be a shareholder of the company. Among them, it does not include preference shareholders, and does not include preference shareholders whose voting rights have been restored.

2. Directors, supervisors, senior managers and persons in charge of information disclosure affairs of the company.
3. Two lawyers (if any) from DeHeng Law Firm hired by the company.

(7) Meeting place
VIP Conference Room, 15th Floor, Block C, Lane 58, Xinjian East Road, Minhang District, Shanghai

2. Matters considered at the meeting
(1) Review the "2020 Annual Report and Its Summary"
The report has been disclosed in the "Annual Report 2020" (Announcement No.: 2021-011) and the "Summary of the 2020 Annual Report" (Announcement Number: 2021-012).

(2) Review the "Special Report on Occupation of Funds in 2020"
The report has been disclosed in the "Special Report on Capital Occupation for 2020" (Announcement No.: 2021-016) published on the Information Disclosure Platform of the National SME Share Transfer System (www.neeq.com.cn).

(3) Review the "2020 Board of Directors Work Report"
The company's board of directors reviewed and discussed the work in 2020, and formed the work report of the board of directors in 2020.

(4) Review of the "2020 Work Report of the Board of Supervisors"
The company's board of supervisors reviewed and discussed the work in 2020, and formed the work report of the board of supervisors in 2020.

(5) Review the "2020 Financial Final Account Report"
The company has summarized the company's 2020 financial status based on the actual situation, and made a 2020 financial statement report.

(6) Review the "2021 Financial Budget Report"
According to the company's 2020 financial statement report and the company's actual situation and subsequent development, the company has formulated the 2021 financial budget.

(7) Review the "2020 Profit Distribution Plan"
According to the company's operating conditions and the "audit report" issued by Lixin Certified Public Accountants (special general partnership), for the long-term development of the company, no profit distribution will be made in 2020.

(8) Review the "Regarding the Renewal of the Appointment of Audit Institutions for 2021"
It is proposed to hire Lixin Certified Public Accountants (special general partnership) as the audit agency in 2021.

There is no special resolution for the above proposal;
There is no cumulative voting proposal for the above proposal;
There is no separate vote counting proposal for small and medium investors in the above proposal;
There is no resolution of related shareholders' withdrawal form for the above-mentioned proposal;
There is no proposal in which preferred shareholders participate in voting on the above proposal.
There is no proposal to review the public offering of stocks and list them on the selection layer.
3. Conference registration method
(1) Registration method
Shareholders attending the meeting shall register with the following documents: natural person shareholders shall hold their own ID cards; if an agent represents individual shareholders to attend this meeting, they shall present the ID card (copy) of the entrusting person and the authorized entrustment signed by the entrusting person The legal person shareholder shall present his ID card and the legal representative’s identity certificate when attending this meeting; if the legal person shareholder entrusts a representative to attend this meeting, he shall present his ID card and stamp The official seal of the unit and a written power of attorney signed by the legal representative; shareholders can register by letter, fax and door-to-door registration. The company does not accept registration by telephone.

(2) Registration time: 9:00 to 11:00 on May 13, 2020

(3) Place of registration: VIP meeting room on the 15th floor, Block C, Lane 58, Xinjian East Road, Minhang District, Shanghai

Four, other
(1) Conference contact information: (1) 1. Contact address: Room 204, Block C, Lane 58, Xinjian East Road, Minhang District, Shanghai. 2. Secretary of the Board: Zhang Wei 3. Telephone: 021-54175679 4. Email: dsh2@ yananpharm.com

(2) Conference expenses: self-care

5. List of available documents
Resolutions of the thirteenth meeting of the second board of directors of Shanghai Yanan Pharmaceutical Yangpu Co., Ltd.

Board of Directors of Shanghai Yan'an Pharmaceutical Yangpu Co., Ltd.
April 20, 2021